3,10-di-p-chlorophenyl-6,12-diazatetrahomocubane compound and synthesis method, application and pharmaceutical composition thereof
A technology of p-chlorophenyl group and a synthesis method, applied in the field of compound synthesis, can solve problems such as digestive tract damage, liver and kidney damage, etc., and achieve the effect of good anti-inflammatory activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0029] Example 1: 3,10-di-p-chlorophenyl-6,12-diazatetraholycubane compounds with the structure shown in formula I
[0030]
Embodiment 2
[0031] Embodiment 2: synthetic experiment is combined with attached figure 1 Description: 3-acetylpyridine and benzyl bromide are used as raw materials: 1.5mL of 3-acetylpyridine is dissolved in 25mL of acetonitrile, 1.8mL of benzyl bromide is added and heated under reflux for 15 hours, after cooling, 30mL of diethyl ether is added to precipitate, and obtained after suction filtration The precipitate was washed with 10 mL of diethyl ether to obtain 3.7 g of white powder a of pyridinium bromide salt, with a yield of 92.8%. (It is normal that the error range of the yield is not more than 5%) Weigh 1.5 g of dry pyridinium bromide salt a and dissolve it in 100 mL of tetrahydrofuran. Slowly add 6 mL of Grignard reagent 4-chlorophenylmagnesium chloride at low temperature (-18°C) under continuous stirring, use CuI0.1g as the catalyst for this reaction, react for 20min under low temperature (-18°C) stirring, and then transfer to The reaction was carried out at room temperature for 30...
Embodiment 3
[0043] Example 3: The present invention also relates to a pharmaceutical composition containing the compound of the present invention as an active ingredient. The pharmaceutical composition can be prepared according to methods known in the art. Any dosage form suitable for human or animal use can be prepared by combining the compounds of the present invention with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants. The content of the compound of the present invention in its pharmaceutical composition is usually 0.1-95% by weight.
[0044] The compound of the present invention or the pharmaceutical composition containing it can be administered in the form of a unit dose, and the route of administration can be enteral or parenteral, such as oral, nasal cavity, oral mucosa, skin, peritoneum, rectum, etc.
[0045] The dosage form for administration may be a liquid dosage form, a solid dosage form or a semi-solid dosage form. Liquid dosage forms c...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


